ZALTRAP SOLUTION

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

AFLIBERCEPT

Verfügbar ab:

SANOFI-AVENTIS CANADA INC

ATC-Code:

L01XX44

INN (Internationale Bezeichnung):

AFLIBERCEPT

Dosierung:

100MG

Darreichungsform:

SOLUTION

Zusammensetzung:

AFLIBERCEPT 100MG

Verabreichungsweg:

INTRAVENOUS

Einheiten im Paket:

4ML/3X4ML

Verschreibungstyp:

Prescription

Therapiebereich:

ANTINEOPLASTIC AGENTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0154950002; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2020-07-13

Fachinformation

PRODUCT MONOGRAPH
Pr
ZALTRAP
™
Aflibercept
Concentrate for solution for infusion, 25 mg/mL
100 mg and 200 mg vials
Antineoplastic agent
ATC code: L01XX44
sanofi-aventis Canada Inc.
2905 Place Louis-R.-Renaud
Laval, Québec H7V 0A3
Date of Preparation:
August 3, 2016
Submission Control No.: 196179
Date of Approval: August 5, 2016
_ _
_ _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND STABILITY
..........................................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................26
PART II: SCIENTIFIC INFORMATION
...............................................................................27
PHARMACEUTICAL INFORMATION
..........................................................................27
CLINICAL TRIALS
..........................................................................................................28
TOXICOLOGY
............